↑ 疾患リストへ ← 戻る

 37. 膿疱性乾癬(汎発型) [臨床試験数:29,薬物数:34(DrugBank:15),標的遺伝子数:15,標的パスウェイ数:18] 

Searched query = "Generalised pustular psoriasis", "Pustular psoriasis", "Herpetic impetigo"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03885089November 30, 201922 October 2019Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Psoriasis)Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis)Psoriasis Vulgaris;Psoriasis Arthropathica;Pustular Psoriasis;Erythrodermic PsoriasisDrug: Infliximab [infliximab biosimilar 3]PfizerNot recruitingN/AN/AAll100Phase 2Japan
2NCT03998683September 3, 201911 November 2019A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular PsoriasisA Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular PsoriasisPsoriasisDrug: Guselkumab 100 mg;Drug: PlaceboJanssen-Cilag Ltd.Recruiting18 YearsN/AAll105Phase 3France;Germany;Italy;Spain;United Kingdom
3NCT03942042July 4, 20192 September 2019A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic PsoriasisA Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic PsoriasisGeneralized Pustular Psoriasis;Erythrodermic PsoriasisDrug: IxekizumabEli Lilly and CompanyRecruiting20 YearsN/AAll12Phase 4Japan
4NCT03886246May 27, 20194 November 2019A 5-year Study to Test BI 655130 in Patients With Generalized Pustular Psoriasis Who Took Part in Previous Studies With BI 655130An Open-label, Long Term Extension Study to Assess the Safety and Efficacy of BI 655130 Treatment in Patients With Generalized Pustular Psoriasis (GPP)Generalized Pustular PsoriasisDrug: SpesolimabBoehringer IngelheimRecruiting18 YearsN/AAll120Phase 3United States;France;Malaysia;Taiwan
5NCT03619902March 4, 201915 July 2019A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular PsoriasisA Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular PsoriasisGeneralized Pustular PsoriasisDrug: ANB019AnaptysBio, Inc.Recruiting18 Years75 YearsAll10Phase 2United States;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2017-004231-37-FR22/01/201928 February 2019A study to test BI 655130 in patients with a flare-up of a skin disease called Generalized Pustular PsoriasisMulti-center, double-blind, randomised, placebo-controlled, Phase II study to evaluate efficacy, safety and tolerability of BI 655130 in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity. - Flare Treatment Phase II Trial in GPPGeneralized Pustular Psoriasis (GPP)
MedDRA version: 20.0 Level: LLT Classification code 10037159 Term: Psoriasis pustular System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Code: BI 655130
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: BI 655130
CAS Number: *MASKED*
Current Sponsor code: BI 655130
Other descriptive name: MONOCLONAL ANTIBODY ANTI-IGG1
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 60-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use
Boehringer Ingelheim FranceAuthorised Female: yes
Male: yes
27Phase 2United States;France;Taiwan;Malaysia;Thailand;Singapore;Germany;Tunisia;Japan;Switzerland
7JPRN-jRCTs03118036720/02/201810 September 2019The effect of infliximab on endothelial function in patients with psoriasisA pilot study for the effect of infliximab on endothelial function in patients with psoriasisPsoriasis vulgaris, Psoriatic arthritis, Pustular psoriasis, Erythrodermic psoriasis
Psoriasis vulgaris, Psoriatic arthritis, Pustular psoriasis, Erythrodermic psoriasis;D011565, D015535
Endothelial function is measured in patients with psoriasis treated with infliximab before and after the first, second, and third infusions.YOSHIHIDE ASANORecruiting>= 20age old< 80age oldBoth25N/Anone
8JPRN-UMIN0000272082017/06/012 April 2019A pilot study for the effect of infliximab on endothelial function in patients with psoriasisPsoriasis vulgaris, Psoriatic arthritis, Pustular psoriasis, Erythrodermic psoriasisEndothelial function is measured in patients with psoriasis treated with infliximab before and after the first, second, and third infusions.The University of Tokyo HospitalRecruiting20years-old80years-oldMale and Female25Not applicableJapan
9NCT03051217February 21, 20174 February 2019A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic PsoriasisPhase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic PsoriasisModerate to Severe Psoriasis;Generalized Pustular Psoriasis and Erythrodermic PsoriasisOther: Placebo;Drug: Certolizumab PegolUCB Biopharma S.P.R.L.Not recruiting20 YearsN/AAll149Phase 2/Phase 3Japan
10NCT03022045January 26, 201711 June 2018A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic PsoriasisA Phase 3, Randomized, Open-Label Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic PsoriasisGeneralized Pustular Psoriasis;Erythrodermic PsoriasisDrug: risankizumabAbbVieNot recruiting20 YearsN/AAll17Phase 3Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02978690December 19, 201629 January 2018BI655130 Single Dose in Generalized Pustular PsoriasisMulti-centre, Open-label, Single Arm, Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacogenomics and Efficacy of a Single Intravenous Dose of BI 655130 in Patients With Active Generalized Pustular Psoriasis.PsoriasisDrug: BI655130Boehringer IngelheimNot recruiting18 Years75 YearsAll7Phase 1France;Japan;Korea, Republic of;Malaysia;Taiwan;Tunisia;Singapore
12EUCTR2015-003600-23-GB01/04/201630 April 2018Comparing Anakinra versus placebo in the treatment of pustular psoriasisTreatment of Pustular Psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studiesAcral Pustular Psoriasis, specifically but not limited to Palmo-Plantar Pustulosis will be the target population for therapeutic intervention with Anakinra in this study.
MedDRA version: 20.0 Level: PT Classification code 10037575 Term: Pustular psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: Anakinra
Product Name: Anakinra
Pharmaceutical Form: Solution for injection
INN or Proposed INN: ANAKINRA
CAS Number: 143090-92-0
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Guy's and St Thomas NHS Foundation TrustAuthorisedFemale: yes
Male: yes
64Phase 4United Kingdom
13NCT02533375September 28, 201516 December 2017Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular PsoriasisGeneralized Pustular Psoriasis (GPP);Adalimumab;JapaneseDrug: AdalimumabAbbVieNot recruiting15 Years75 YearsAll10Phase 3Japan
14NCT02343744January 19, 20154 November 2019An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisA Phase 3, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of CNTO1959 (Guselkumab) in the Treatment of Subjects With Generalized Pustular Psoriasis or Erythrodermic PsoriasisPustular PsoriasisDrug: GuselkumabJanssen Pharmaceutical K.K.Not recruiting20 YearsN/AAll21Phase 3Japan
15JPRN-JapicCTI-14243001/2/20142 April 2019A Phase 3 Clinical Study of KHK4827An Extension Study of KHK4827 Subjects with Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic ErythrodermaPsoriasisIntervention name : KHK4827
INN of the intervention : brodalumab
Dosage And administration of the intervention : Subcutaneous administration
Control intervention name : null
Kyowa Hakko Kirin Co., Ltd.18BOTH165Phase 3
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT02052609February 20144 November 2019A Phase 3 Clinical Study of KHK 4827An Extension Study of KHK4827 in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic ErythrodermaPsoriasis Vulgaris;Psoriatic Arthritis;Pustular; Psoriasis, Palmaris Et Plantaris;Psoriatic ErythrodermaDrug: KHK4827 140mg SC;Drug: KHK4827 210mg SCKyowa Kirin Co., Ltd.Not recruiting18 YearsN/AAll155Phase 3Japan
17NCT02008890December 26, 201314 January 2019Palmoplantar Pustular Psoriasis Efficacy and Safety With SecukinumabA 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Palmoplantar Pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 Weeks of Treatment, Compared to Placebo, and to Assess Long-term Safety, Tolerability, and Efficacy in Subjects With Moderate to Severe Chronic Palmoplantar Pustular Psoriasis - Amended With an Optional Extension Treatment Period of up to a Total of 148 WeeksPalmoplantar Pustular PsoriasisBiological: Secukinumab 300mg;Biological: Secukinumab 150mg;Biological: PlaceboNovartis PharmaceuticalsNot recruiting18 YearsN/AAll237Phase 3Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
18EUCTR2013-003086-34-SE04/12/20132 October 2017Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects with Moderate to Severe Chronic Palmoplantar Pustular PsoriasisA 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 weeks of treatment, compared to placebo, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe chronic palmoplantar pustular psoriasisModerate to severe chronic palmoplantar pustular psoriasis
MedDRA version: 16.1 Level: PT Classification code 10037575 Term: Pustular psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
MedDRA version: 16.1 Level: LLT Classification code 10037158 Term: Psoriasis palm & soles System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: Secukinumab
Product Code: AIN457
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: SECUKINUMAB
CAS Number: 1229022-83-6
Other descriptive name: SECUKINUMAB
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe
Route of administration of the placebo: Subcutaneous use
Novartis Pharma Services AGNot RecruitingFemale: yes
Male: yes
210Phase 3France;Spain;Belgium;Poland;Austria;Russian Federation;Germany;United Kingdom;Italy;Sweden
19NCT01952015August 21, 201325 March 2019Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)A Multi-center, Open Label Study of Subcutaneous Secukinumab in Prefilled Syringes as Mono- or Co-therapy to Assess the Efficacy, Safety and Tolerability in Japanese Subjects With Generalized Pustular PsoriasisPsoriasisBiological: SecukinumabNovartis PharmaceuticalsNot recruiting18 YearsN/AAll12Phase 3Japan
20JPRN-JapicCTI-13230501/8/20132 April 2019Study to assess the efficacy, safety and tolerability of secukinumab in Japanese subjects with GPPA multi-center, open label study of subcutaneous secukinumab in prefilled syringes as mono- or co-therapy to assess the efficacy, safety and tolerability up to 52 weeks in Japanese subjects with generalized pustular psoriasisGeneralized Pustular Psoriasis (GPP)Intervention name : AIN457
INN of the intervention : Secukinumab
Dosage And administration of the intervention : Secukinumab 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose)
Control intervention name : null
Novartis Pharma K.K.18BOTHPhase 3
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT01794117July 1, 201322 October 2019Anakinra for Inflammatory Pustular Skin DiseasesA Phase 2 Study of Anakinra in Inflammatory Pustular Dermatoses: Evaluation of Therapeutic Efficacy and Validation of Pathogenic MechanismsSneddon-Wilkinson;Acrodermatitis Continua of Hallopeau;Pustular Psoriasis;Palmoplantar PustulosisDrug: AnakinraNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Not recruiting18 Years110 YearsAll18Phase 2United States
22JPRN-JapicCTI-13205701/2/20132 April 2019An open-label, non-controlled study of KHK4827 in subjects with psoriasisA Long-Term Study of KHK4827 in Subjects with Pustular Psoriasis (Generalized) and Psoriatic ErythrodermaPsoriasisIntervention name : KHK4827
INN of the intervention : brodalumab
Dosage And administration of the intervention : Subcutaneous administration
Control intervention name : null
Kyowa Hakko Kirin Co., Ltd.18BOTHPhase 3
23NCT01782937February 20132 March 2015An Open-label, Non-controlled Study of KHK4827 in Subjects With PsoriasisA Long-Term Study of KHK4827 in Subjects With Pustular Psoriasis (Generalized) and Psoriatic ErythrodermaPsoriasisDrug: KHK4827Kyowa Hakko Kirin Company, LimitedNot recruiting18 YearsN/ABoth30Phase 3Japan
24NCT01680159July 201216 December 2017A Clinical Study of Increased Dose of TA-650 in Patients With PsoriasisPlaque Psoriasis;Psoriatic Arthritis;Pustular Psoriasis (Excluding a Localized);Psoriatic ErythrodermaDrug: TA-650Mitsubishi Tanabe Pharma CorporationNot recruiting16 Years75 YearsAll51Phase 3Japan
25ChiCTR-TRC-120035422011-08-0118 April 2017A Multi-center, randomized, double-blinded, double-dummy, parallel-controlled clinical trial to determine the efficacy and safety of Tripterygium Glycosides and Acitretin in patients with generalized pustular psoriasisGuideline-oriented Research in the Management of Some Common and Severe Skin DiseasesGeneralized pustular psoriasisTG treatment group:Take TG tablet 2 slices every time, thrice a day, the placebo of Acitretin Capsules 2 pills every time, twice a day;Acitretin treatment group:Take the placebo of TG tablet 2 slices every time, thrice a day, Acitretin Capsules 2 pills every time, twice a day;Institute of dermatology, Chinese Academy of Medical SciencesNot Recruiting1675BothTG treatment group:180;Acitretin treatment group:180;Post-marketChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT01091051March 201019 February 2015Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar PustulosisSafety and Efficacy of Ustekinumab in the Treatment of Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar PustulosisPalmo-Plantar Pustular Psoriasis;Palmo-Plantar PustulosisDrug: Ustekinumab;Drug: Placebo (Soduim Chloride)Innovaderm Research Inc.Janssen-Ortho LLCNot recruiting18 YearsN/ABoth33Phase 3Canada
27EUCTR2007-003922-70-DE28/11/200719 March 2012Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP) - PPP StudyUncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP) - PPP Studymoderate to severe palmoplantar pustular psoriasis
MedDRA version: 9.1 Level: LLT Classification code 10037159 Term: Psoriasis pustular
Trade Name: Raptiva
Pharmaceutical Form: Concentrate and solvent for solution for injection
INN or Proposed INN: Efalizumab
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 100-
Technische Universität DresdenNot RecruitingFemale: yes
Male: yes
42Phase 2aGermany
28EUCTR2006-005344-83-DE09/02/200719 March 2012A Randomized, Double-blind, Placebo and Active Treatment-Controlled Study in Psoriatic Patients to Assess the Tolerability, Pharmacokinetics and Efficacy of a Cream Formulation Containing 3% of P32/98A Randomized, Double-blind, Placebo and Active Treatment-Controlled Study in Psoriatic Patients to Assess the Tolerability, Pharmacokinetics and Efficacy of a Cream Formulation Containing 3% of P32/98Psoriasis is a common inherited autoimmune disease that affects 2-3% of the world-wide population. There are several recognized forms of psoriasis, such as plaque psoriasis, which is also known as psoriasis vulgaris and guttate, inverse, erythrodermic and pustular psoriasis, which can coexist within the same patient. The most common form is the plaque psoriasis.
MedDRA version: 8.1 Level: LLT Classification code 10037153 Term: Psoriasis
Product Name: P32/98 3%
Product Code: P32/98
Pharmaceutical Form: Cream
CAS Number: 251572-86-8
Current Sponsor code: P32/98
Concentration unit: % percent
Concentration type: equal
Concentration number: 3-
Pharmaceutical form of the placebo: Cream
Route of administration of the placebo: Topical use (Noncurrent)
Trade Name: Silikis 3µg/g Salbe
Pharmaceutical Form: Ointment
INN or Proposed INN: Calcitriol
Concentration unit: µg/kg microgram(s)/kilogram
Concentration type: equal
Concentration number: 3000-
Probiodrug AGNot RecruitingFemale: yes
Male: yes
Germany
29NCT00301002June 200519 February 2015Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar PustulosisA Pilot Open-Label Study to Evaluate the Safety and Observe the Effectiveness of 16 Weeks of Alefacept in Palmar Plantar Pustulosis (IST 92)Psoriasis;Palmoplantaris Pustulosis;Pustular Psoriasis of Palms and Soles;Pustulosis Palmaris et Plantaris;Pustulosis of Palms and SolesDrug: AlefaceptThe Guenther Dermatology Research CentreBiogen IdecNot recruiting18 YearsN/ABoth15Phase 2Canada

先頭へ